The Medicines Co. falls on discontinuation of Phase 2b trial of MDCO-2010 The stock has spiked lower today after the company yesterday reported it had discontinued the Phase 2b trial of MDCO-2010. Support is now at $24.94. Resistance is at $26.
News For MDCO From The Last 14 Days
Check below for free stories on MDCO the last two weeks.
The Medicines Co. weakness not related to fundamentals, says ISI Group ISI Group said they spoke with The Medicines Company management and haven't found anything fundamental to explain today's weakness. The analyst also confirmed there was nothing new regarding the ongoing Angiomax litigation with the Judge's office and said today's AcelRx Ph. 3 data provided no new information.
The Medicines Co. increases on wide intra-day price movement The Medicines Co. June call option implied volatility is at 42, July is at 53, October is at 49; compared to its 26-week average of 39 according to Track Data, suggesting large price movement.